Drug profile · INN
fostemsavir tromethamine
RUKOBIA
fostemsavir tromethamine (RUKOBIA) is a envelope polyprotein gp160 inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — fostemsavir tromethamine
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
fostemsavir tromethamine (RUKOBIA) is a envelope polyprotein gp160 inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Envelope polyprotein GP160 inhibitor
Primary target: Envelope glycoprotein gp160
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is fostemsavir tromethamine?
fostemsavir tromethamine (RUKOBIA) is a envelope polyprotein gp160 inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for fostemsavir tromethamine?
RUKOBIA is a marketed brand name for fostemsavir tromethamine. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of fostemsavir tromethamine?
fostemsavir tromethamine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.